Physician

Andrew Philip Zinn

According to 2025 Medicare claims, Andrew Zinn (NPI: 1366632432) practices interventional cardiology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is CARDIOVASCULAR ASSOCIATES OF THE DELAWARE VALLEY,P A (NPI: 1366495632; TIN: 223321233) and primary practice location at 08035-1994.

Zinn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,246 traditional Medicare patients, billed 3,190 HCPCS/CPT codes, and received $417,067 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,485 prescription claims across 399 beneficiaries totaling $447,583 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 22 claims. Open Payments data shows 50 records totaling $1,023. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $66,169 to $447,583. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $49,448 to $7,274.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,874	5,269	$339,655
2016	1,575	4,252	$318,459
2017	1,951	4,226	$310,546
2018	1,501	3,147	$250,805
2019	1,668	3,472	$275,506
2020	1,240	2,806	$284,719
2021	1,116	2,775	$322,622
2022	962	2,516	$427,089
2023	1,128	2,946	$596,728
2024	1,246	3,190	$417,067

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	178	920	$66,169
2016	197	1,226	$91,418
2017	201	1,222	$97,225
2018	213	1,164	$93,424
2019	229	1,472	$161,295
2020	259	1,648	$230,528
2021	268	1,484	$236,095
2022	291	1,709	$269,673
2023	335	2,029	$385,256
2024	399	2,485	$447,583

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	35	$49,253
2016	N/R	N/R	N/R
2017	N/R	17	$36,266
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	22	$730
2022	N/R	N/R	N/R
2023	N/R	22	$814
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	197	239	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	199	251	$69
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	194	260	$69
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	203	269	$14
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	195	271	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	109	5,882	$110,174
Xarelto	Rivaroxaban	91	5,459	$96,930
Entresto	Sacubitril/Valsartan	73	4,440	$93,115
Farxiga	Dapagliflozin Propanediol	47	2,250	$41,021
Repatha Sureclick	Evolocumab	32	1,619	$30,926

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	50	$1,023	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew Philip Zinn?

Tedicare shows public-source Medicare data for Andrew Philip Zinn (NPI 1366632432), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew Philip Zinn have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew Philip Zinn?

Andrew Philip Zinn is linked to CARDIOVASCULAR ASSOCIATES OF THE DELAWARE VALLEY,P A (billing NPI 1366495632) in the available physician profile data.

Does Andrew Philip Zinn have Open Payments data?

Andrew Philip Zinn has 50 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.